The U.S. FDA approved a combination of a molecularly targeted therapeutic and an immunotherapeutic to treat certain patients with uterine cancer. The U.S. Food and Drug Administration (FDA) approved the combination of the immunotherapeutic...
Recently published clinical trial results suggest that combining an investigational antibody therapy with chemotherapy may be an effective strategy for patients with relapsed disease.
A study measures the global impact of alcohol on cancer incidence, and more news of the week from Cancer Today.
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today Cancers that grow and disseminate to threaten life reside amid many types of noncancerous cells, including blood vessel cells, supportive cells called fibroblasts, and...
Study shows cancer centers can improve coordination with physicians’ practices in their networks, and more news of the week from Cancer Today.
The U.S. FDA approved a monoclonal antibody and enzyme combination for use in conjunction with chemotherapy and a steroid to treat patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) approved...
The U.S. FDA approved an antibody-drug conjugate to treat urothelial cancer, the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic enfortumab vedotin-ejfv (Padcev) to...
A study sheds light on the link between red meat consumption and colorectal cancer, and more news of the week from Cancer Today.
Despite progress, the Florida study found that the breast cancer death rate for Black women remained higher than for White women. The disparity gap in breast cancer survival rates between Black and white women...
The U.S. FDA approved a new chemotherapy as part of a multi-drug regimen for certain patients with two similar blood cancers. The U.S. Food and Drug Administration (FDA) approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze)...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More